faktor vii nf takeda injektionspräparat
takeda pharma ag - fattore vii coagulationis humanus - injektionspräparat - praeparatio cryodesiccata: proteinum humanum 50-200 mg corresp. factor vii coagulationis humanus 600 u.i., heparinum natricum, natrii citras dihydricus, natrii chloridum, pro vitro. solvens: aqua ad iniectabile 10 ml. - fattore vii mancanza - emoderivati
ninlaro 2.3 mg capsule rigide
takeda pharma ag - ixazomibum - capsule rigide - ixazomibum 2.3 mg ut ixazomibi citras, cellulosum microcristallinum, talcum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (rubrum), drucktinte: lacca, propylenglycolum, kalii hydroxidum, ammoniae solutio 30 per centum, e 172 (nigrum), pro capsula. - onkologikum - synthetika
ninlaro 3.0 mg capsule rigide
takeda pharma ag - ixazomibum - capsule rigide - ixazomibum 3 mg ut ixazomibi citras, cellulosum microcristallinum, talcum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (nigrum), drucktinte: lacca, propylenglycolum, kalii hydroxidum, ammoniae solutio 30 per centum, e 172 (nigrum), pro capsula. - onkologikum - synthetika
ninlaro 4.0 mg capsule rigide
takeda pharma ag - ixazomibum - capsule rigide - ixazomibum 4 mg ut ixazomibi citras, cellulosum microcristallinum, talcum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), e 172 (rubrum), drucktinte: lacca, propylenglycolum, kalii hydroxidum, ammoniae solutio 30 per centum, e 172 (nigrum), pro capsula. - onkologikum - synthetika
fosrenol 500 mg compresse masticabili
takeda pharma ag - lantanio - compresse masticabili - lanthanum 500 mg ut lanthani(iii) carbonas hydricum 954 mg, saccharida hydrica corresp. glucosum 1055.736 mg, silica colloidalis anhydrica, magnesii stearas, pro compresso. - sostanza che lega il fosfato - synthetika
fosrenol 750 mg compresse masticabili
takeda pharma ag - lantanio - compresse masticabili - lanthanum 750 mg ut lanthani(iii) carbonas hydricum 1431 mg, saccharida hydrica corresp. glucosum 1583.604 mg, silica colloidalis anhydrica, magnesii stearas, pro compresso. - sostanza che lega il fosfato - synthetika
fosrenol 1000 mg compresse masticabili
takeda pharma ag - lantanio - compresse masticabili - lanthanum 1000 mg ut lanthani(iii) carbonas hydricum 1908 mg, saccharida hydrica corresp. glucosum 2111.472 mg, silica colloidalis anhydrica, magnesii stearas, pro compresso. - sostanza che lega il fosfato - synthetika
xagrid 0,5 mg capsule rigide
takeda pharma ag - anagrelidum - capsule rigide - anagrelidum 0.5 mg ut anagrelidi hydrochloridum monohydricum, povidonum k 30, lactosum 65.76 mg, lactosum monohydricum 53.74 mg, cellulosum microcristallinum, crospovidonum, magnesii stearas, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, e 172 (nigrum), pro capsula. - trattamento della trombocitemia essenziale - synthetika
replagal durchstechflasche à 3.5 ml infusionskonzentrat
takeda pharma ag - agalsidasum alfa - infusionskonzentrat - agalsidasum alfa 1 mg, natrii dihydrogenophosphas monohydricus, polysorbatum 20, natrii chloridum, natrii hydroxidum q.s. ad ph, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 4.1 mg. - enzymersatz terapia nei pazienti con malattia di fabry (alfa-galattosidasi a mancanza) - biotechnologika
equasym xr 10 mg; retardkapseln equasym xr 10 mg; retardkapseln
takeda pharma ag - methylphenidati hydrochloridum - equasym xr 10 mg; retardkapseln - methylphenidati hydrochloridum 10 mg, sacchari sphaerae corresp. saccharum 34.1-49.5 mg et maydis amylum, povidonum, hypromellosum, macrogola, ethylcellulosum, dibutylis sebacas, kapselhülle: gelatina, e 132, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, natrii hydroxidum, povidonum, ammoniae solutio 28 per centum, e 171, e 172 (nigrum) pro capsula. - adhs, adhd - synthetika